LY404039 - CAS 635318-11-5
Catalog number: B0084-146172
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C7H9NO6S
Molecular Weight:
235.22
COA:
Inquire
Targets:
mGluR
Description:
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-146172 50 mg $398 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
GW786034 HCl; LY-404039; LY 404039; LY404039; LY-404,039; LY404,039; LY 404,039; Pomaglumetad
MSDS:
Inquire
InChIKey:
AVDUGNCTZRCAHH-MDASVERJSA-N
InChI:
InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
Canonical SMILES:
C1C(C2C(C2S1(=O)=O)C(=O)O)(C(=O)O)N
1.Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Deutschenbaur L1, Beck J1, Kiyhankhadiv A1, Mühlhauser M1, Borgwardt S1, Walter M1, Hasler G1, Sollberger D1, Lang UE2. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:325-33. doi: 10.1016/j.pnpbp.2015.02.015. Epub 2015 Mar 4.
Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has been observed by ketamine, which acts via the glutamatergic system. Hence, a steady accumulation of evidence supporting a role for the excitatory amino acid neurotransmitter (EAA) glutamate in the treatment of depression has been observed in the last years. Emerging evidence indicates that N-methyl-D-aspartate (NMDA), group 1 metabotropic glutamate receptor antagonists and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) agonists have antidepressant properties. Indeed, treatment with NMDA receptor antagonists has shown the ability to sprout new synaptic connections and reverse stress-induced neuronal changes. Based on glutamatergic signaling, a number of therapeutic drugs might gain interest in the future. Several compounds such as ketamine, memantine, amantadine, tianeptine, pioglitazone, riluzole, lamotrigine, AZD6765, magnesium, zinc, guanosine, adenosine aniracetam, traxoprodil (CP-101,606), MK-0657, GLYX-13, NRX-1047, Ro25-6981, LY392098, LY341495, D-cycloserine, D-serine, dextromethorphan, sarcosine, scopolamine, pomaglumetad methionil, LY2140023, LY404039, MGS0039, MPEP, 1-aminocyclopropanecarboxylic acid, all of which target this system, have already been brought up, some of them recently.
2.Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.
Ahnaou A1, Biermans R1, Drinkenburg WH1. PLoS One. 2016 Jan 25;11(1):e0147365. doi: 10.1371/journal.pone.0147365. eCollection 2016.
Improvement of cognitive impairments represents a high medical need in the development of new antipsychotics. Aberrant EEG gamma oscillations and reductions in the P1/N1 complex peak amplitude of the auditory evoked potential (AEP) are neurophysiological biomarkers for schizophrenia that indicate disruption in sensory information processing. Inhibition of phosphodiesterase (i.e. PDE10A) and activation of metabotropic glutamate receptor (mGluR2) signaling are believed to provide antipsychotic efficacy in schizophrenia, but it is unclear whether this occurs with cognition-enhancing potential. The present study used the auditory paired click paradigm in passive awake Sprague Dawley rats to 1) model disruption of AEP waveforms and oscillations as observed in schizophrenia by peripheral administration of amphetamine and the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP); 2) confirm the potential of the antipsychotics risperidone and olanzapine to attenuate these disruptions; 3) evaluate the potential of mGluR2 agonist LY404039 and PDE10 inhibitor PQ-10 to improve AEP deficits in both the amphetamine and PCP models.
3.Hydrophilic interaction chromatography with aerosol-based detectors (ELSD, CAD, NQAD) for polar compounds lacking a UV chromophore in an intravenous formulation.
Cintrón JM1, Risley DS. J Pharm Biomed Anal. 2013 May 5;78-79:14-8. doi: 10.1016/j.jpba.2013.01.022. Epub 2013 Jan 26.
In this work, a high performance liquid chromatography (HPLC) method is reported for the separation and quantitation of a drug substance that is highly polar and lacking a chromophore in a mannitol intravenous (IV) formulation. Three polar stationary phases operated in hydrophilic interaction chromatography (HILIC) mode were evaluated in conjunction with an Alltech 800 ELSD detector. These columns were evaluated with respect to chromatographic properties such as buffer, pH and organic concentrations to identify the best stationary phase. The chromatographic method was then validated for the determination of mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-Amino-2-sulfonylbicyclo [3.1.0] hexane-4,6-dicarboxylic acid (LY404039) content in a mannitol IV formulation with respect to linearity (R(2) of 0.9997), repeatability (%RSD of 0.36%), accuracy, solution stability (99.56% after 24h), specificity, intra-assay precision (%RSD 0.48%) and limit of detection (LOD, ∼50 μg/mL).
4.In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.
Moulton RD1, Ruterbories KJ2, Bedwell DW2, Mohutsky MA2. Drug Metab Dispos. 2015 May;43(5):756-61. doi: 10.1124/dmd.114.062893. Epub 2015 Mar 9.
To characterize the hydrolysis of the peptide prodrug pomaglumetad methionil (LY2140023; (1R,4S,5S,6S)-4-(L-methionylamino)-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide), to the active drug LY404039 [(1R,4S,5S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide], a series of in vitro studies were performed in various matrices, including human intestinal, liver, kidney homogenate, and human plasma. The studies were performed to determine the tissue(s) and enzyme(s) responsible for the conversion of the prodrug to the active molecule. This could enable an assessment of the risk for drug interactions, an evaluation of pharmacogenomic implications, as well as the development of a Physiologically Based Pharmacokinetic (PBPK) model for formation of the active drug. Of the matrices examined, hydrolysis of pomaglumetad methionil was observed in intestinal and kidney homogenate preparations and plasma, but not in liver homogenate.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products


CAS 97075-46-2 AMN 082 dihydrochloride

AMN 082 dihydrochloride
(CAS: 97075-46-2)

The hydrochloride salt form of AMN 082 has been found to be a mGlu7 agonist.

CAS 1309976-62-2 VU 0360172 hydrochloride

VU 0360172 hydrochloride
(CAS: 1309976-62-2)

VU 0360172 hydrochloride is a positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM) with potential antipsychotic-like activity. VU 036017...

CAS 1161205-04-4 VU 0361737

VU 0361737
(CAS: 1161205-04-4)

VU 0361737 is a selective positive allosteric modulator (PAM) for mGlu4 receptor with EC50 of 240 nM and 110 nM at human and rat receptors, respectively, displa...

CAS 1186195-60-7 MTEP hydrochloride

MTEP hydrochloride
(CAS: 1186195-60-7)

Glutamate, the major excitatory neurotransmitter in the brain, acts on both ionotropic and metabotropic glutamate receptors. Excessive metabotropic glutamate re...

CAS 201730-11-2 DCPG

DCPG
(CAS: 201730-11-2)

DCPG is a potent and selective mGlu8a agonist (EC50 = 31 nM) displaying > 100-fold selectivity over mGlu1-7. It increases c-Fos expression in stress-related bra...

CAS 1227301-51-0 Philanthotoxin 74

Philanthotoxin 74
(CAS: 1227301-51-0)

Philanthotoxin 74, also called as PhTx-74, is a synthetic analog of the naturally-occurring wasp venom toxin philanthotoxin-4,3,3. Philanthotoxin 74 is an AMPA ...

CAS 198419-90-8 (±)-LY 367385

(±)-LY 367385
(CAS: 198419-90-8)

(±)-LY367385 is a selective mGlu1a antagonist.

CAS 1254977-87-1 JNJ-42153605

JNJ-42153605
(CAS: 1254977-87-1)

JNJ-42153605 is a selective positive allosteric modulator of the metabotropic glutamate 2 (mGlu2) receptor (EC50= 17 Nm) with an acceptable pharmacokinetic prof...

Chemical Structure

CAS 635318-11-5 LY404039

Quick Inquiry

Verification code

Featured Items